PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) has cemented a collaboration with renowned cell therapy leaders Professors Georg Schett and Andreas Mackensen to initiate a Phase 1/2 trial ...

Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.

PHILADELPHIA - Century Therapeutics, Inc. (NASDAQ: IPSC), a biotechnology firm with a market capitalization of $77.32 million ...

Century Therapeutics (IPSC) has entered into an agreement for an investigator-initiated Phase 1/2 trial by Professors Georg Schett and Andreas ...